Tumor-Free Circulating Tumor DNA in Node-Negative Rectal Cancers Undergoing Neoadjuvant Chemotherapy, Excision, and Observation in the Phase II NEO Trial (CO.28). Co-authored by @jonathanloree. Read the full article. bit.ly/3VkbzYn

Tissue-Free ctDNA Assay in Early-Stage Rectal Cancer: NEO Trial A new analysis from the phase II CCTG CO.28 NEO trial evaluated a tissue-free epigenomic ctDNA assay in patients with node-negative rectal cancer treated with neoadjuvant chemotherapy followed by transanal excision. Key findings: • ctDNA detection decreased from 45.8% before chemotherapy to 8.7% after treatment. • All 4 patients with detectable postchemotherapy ctDNA were recommended total mesorectal excision, compared with 38.1% of those without detectable ctDNA (P = .03). • Five recurrences occurred during follow-up, and ctDNA status was not significantly associated with recurrence-free survival. • The findings support further evaluation of ctDNA as a supplemental tool alongside MRI, endoscopy, and other clinical assessments. @jonathanloree @caycedomarula @HKennecke @oncodaily oncodaily.com/gastrointestin… #RectalCancer #ctDNA #OncoDaily

Standard vs. reduced dose of everolimus for patients with advanced NETs...? A retrospective study of 170 patients from Mayo Clinic and University Hospitals in Cleveland. @sonbol_bassam @Faresjamall @PatrickMcGarrah and others not found on X. Key findings: -- Patients in the reduced-dose cohort were older, with worse PS and more heavily pretreated -- Median OS was shorter in the reduced dose cohort, 43.7 vs. 81.5 months (p=0.02) -- After multivariate adjustment, the difference was no longer statistically significant -- Similarly, the observed difference in PFS (7 vs. 12.4 months), was no longer significant after adjusting -- Almost half of the full-dose starters needed dose reduction Lower doses may be reasonable in patients expected to have poor tolerance but cannot be routinely recommended. A prospective trial (NCT06472388) is ongoing, led by @RachelRiechelm2 onlinelibrary.wiley.com/doi/…

Seriously, let’s find #Exercizumab!🏃‍♀️ Over a year since the landmark @CDNCancerTrials #CHALLENGE study was published @NEJM …and we can’t seem to implement! Thanks to @nytimes for keeping this in front of the public and our patients. It Can Keep Cancer in Remission. Why Is No One Talking About It? nytimes.com/2026/10/06/well/…

Have you ever wondered what the outcomes are of patients with small bowel NETs and liver mets following cytoreductive hepatectomy if there is co-existing carcinoid heart disease (CHD)? Are the outcomes different in the CHD population when compared to those without CHD? As it seems, probably not. In this retrospective study done at Mayo Clinic, the outcomes of 311 patients were analyzed. 163 had nonfunctional NETs, 110 had carcinoid syndrome (CS) and 38 had CS + CHD. Median overall survival after debulking was very similar, 12.5 vs. 9.1 vs 11.4 years. With optimal cardiac management, cytoreductive hepatectomy in CHD is feasible and provides long-term survival comparable to patients without CHD. Careful multidisciplinary evaluation and management is key. onlinelibrary.wiley.com/doi/… @MayoCancerCare @MayoClinicSurg

This is an absolutely outstanding review on the management of patients with metastatic gastric cancer. I may have posted about this review before but it is so good that it deserves another round of applause... Thanks @KlempnerSam @YJanjigianMD @amalsargsyan and all the other co-authors I could not find on X... Sorry AI, I love you but you are just not there yet. True content experts writing a practical review still beat you easily. This should be a required read for all who take care of patients with gastric cancer. nature.com/articles/s41571-0…

#CCTG2026 @CDNCancerTrials 🇨🇦 A pleasure to host @JeanneTie to our CCTG Annual Meeting to advance our strong history of trials collaboration with @GICancer #formerlyAGITG 🇦🇺 🇳🇿 Special shout out to her #ILoveCanada earrings! ❤️

🌐 BATTMAN trial begins in MSS metastatic colorectal cancer On April 1, 2026, Agenus announced that the first patient has been enrolled in the phase III BATTMAN trial. BATTMAN is a global, randomized phase III study evaluating botensilimab + balstilimab vs best supportive care in patients with refractory, unresectable MSS metastatic colorectal cancer. The trial is being conducted across international sites and represents a potential registrational study in this setting. @Agenus_Bio @oncodaily @jonathanloree @garo_armen 📎oncodaily.com/oncolibrary/ba… #OncoDaily #GIOncology #ColorectalCancer #Immunotherapy #ClinicalTrials

Sharing the final publication and schema! @NANETS1 Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors doi.org/10.1530/ERC-25-0303

@OHSUKnight study showed standard dose (35mg/m2 bid) Trifluridine (Lonsurf) wk 1, 3 and 5 of #radiation for stage 2/3 #rectalcancer was safe with TNT. 56% of patients did Watch and Wait. ➡️New option for patients with 5-FU toxicity/contraindications❓ clinical-colorectal-cancer.c…

Check out our new @NANETS Guidelines for Stage I-III Rectal NETs! Big updates in: - staging with MRI & PET Dotatate - advanced excision for < vs. >10 mm tumors - management of R1 excision - surgery - follow-up @AmanChauhanMD @OncoThor @FlavioRochaMD doi.org/10.1530/ERC-25-0303

Congrats @RobertoFedrigo on your new manuscript on treatment attrition in NETs! Shows how many patients never reach later lines of therapy. Important context as we interpret NETTER-2 and debate earlier PRRT use. sciencedirect.com/science/ar… #NETs #PRRT #NETTER2 #oncology

How would you prefer to be screened for colorectal cancer? 🩺 We’re surveying people to better understand preferences — including whether blood-based tests could reduce barriers. Please retweet & Share your voice: rc.bcchr.ca/redcap/surveys/?… @BCCancer @bccancerfdn @coloncanada

Applications are being accepted for the #CCTG 2026-2027 New Investigator Cancer Trials Practicum - a training program that enables the brightest new Canadian oncology researchers to acquire training & experience in clinical trial conduct. How to apply: buff.ly/pVU9ts3

AI meets digital pathology! 🔬 We used machine learning on whole-slide images of neuroendocrine tumors to classify grade, differentiation & prognosis. ✍ Authors: Amir Hadjifaradji et al. @jonathanloree @BCCancer @bccancerfdn 🌻 Read in @Cancers_MDPI mdpi.com/2072-6694/17/18/299…

A nice retrospective study looking at chemo doublets in biliary tract cancer. "FOLFOX Versus FOLFIRI as Second‐Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study - Pircher - 2026" onlinelibrary.wiley.com/doi/…

RT @EricTopol: The "Big Bang" of cancer evolution: for colon cancer, evidence that immune evasion occurs very early nature.com/articles/s41588-0…

So Dill started this to help Canadian patients... and once he got the platform running for Canada... he made it global. In a weekend. Oh, Canada! @ccranorg @coloncanada @CAMO_ACOM @CDNCancerTrials @uoftmedicine @Sunnybrook @BCCancer @GillSharlene @jonathanloree @ocall0

Results from DYNAMIC-III RCT of ctDNA-guided adjuvant tx in stage III colon cancer in Nature Med. 🙏 to pts, providers & @JeanneTie 🇨🇦🇦🇺 @CDNCancerTrials & @GICancer Collab #ESMO2025 Presidential | Supported by @CIHR_IRSC & @cancersociety in 🇨🇦 🔗 rdcu.be/eLTj8

Excited to be at the #ESMO25 launch of the phase 3 @CDNCancerTrials 🇨🇦 #BATTMAN CO.33 BOT/BAL vs BSC in refractory MSS mCRC #unmetneed #trialsthatmatter Congrats to @jonathanloree 🙌 @ocall0 @Agenus_Bio @GICancer @JeanneTie Let’s get this done! 🇨🇦 🇦🇺 🇫🇷 @coloncanada @ccranorg @OncoAlert